Aridis Pharmaceuticals (ARDS) News Today → Exposed: 10 CENT Crypto to Explode May 20th? (From True Market Insiders) (Ad) Free ARDS Stock Alerts $0.06 0.00 (-2.99%) (As of 01:18 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative March 14, 2024 | uk.investing.comAridis Pharmaceuticals Inc (ARDS)February 10, 2024 | bbc.co.ukIrish Cup: Institute's quarter-final place confirmed as IFA rejects Ards protestDecember 15, 2023 | finance.yahoo.comAridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024November 3, 2023 | markets.businessinsider.comAridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business UpdateNovember 3, 2023 | finance.yahoo.comAridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business UpdateNovember 1, 2023 | morningstar.comAridis Pharmaceuticals Inc ARDSOctober 22, 2023 | benzinga.comAridis Pharmaceuticals Stock (OTC:ARDS), Analyst Ratings, Price Targets, PredictionsOctober 21, 2023 | msn.comHC Wainwright & Co. Maintains Aridis Pharmaceuticals (ARDS) Buy RecommendationOctober 20, 2023 | markets.businessinsider.comFDA’s Qualified Infectious Disease Product Designation Bolsters Aridis Pharmaceuticals’ Investment Appeal: An Analyst’s Buy RecommendationSeptember 15, 2023 | finance.yahoo.comARDS Sep 2023 2.500 callSeptember 15, 2023 | finance.yahoo.comAridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report(R) on Bloomberg TVAugust 21, 2023 | investing.comAridis Pharma (ARDS) Earnings Dates & ReportsAugust 2, 2023 | finance.yahoo.comAridis Pharmaceuticals Announces $2 Million OfferingJuly 18, 2023 | finance.yahoo.comWhy Are Aridis Pharmaceuticals Shares Moving Higher Today?July 17, 2023 | finance.yahoo.comAridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301July 13, 2023 | finance.yahoo.comAridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301July 12, 2023 | finance.yahoo.comAridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) DesignationJune 22, 2023 | marketwatch.comAridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)June 20, 2023 | finance.yahoo.comAridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)June 9, 2023 | finanznachrichten.deAridis Pharmaceuticals, Inc.: Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business UpdateJune 8, 2023 | finance.yahoo.comAridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business UpdateJune 1, 2023 | benzinga.comAridis Pharmaceuticals Stock (NASDAQ:ARDS), Guidance and ForecastMay 31, 2023 | finance.yahoo.comAridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study DesignMay 25, 2023 | finance.yahoo.comAridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-QApril 26, 2023 | finance.yahoo.comAridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-KApril 3, 2023 | bizjournals.comBig pharma, small drug maker spar over pneumonia drug dealMarch 31, 2023 | finance.yahoo.comAridis Provides Corporate UpdateMarch 29, 2023 | msn.comAstraZeneca Axes Pneumonia Drug Pact With AridisMarch 14, 2023 | msn.comWhy Aridis Pharmaceuticals Shares Are DivingMarch 14, 2023 | marketwatch.comAridis Pharmaceuticals Shares Tumble After Stock Offering >ARDSMarch 14, 2023 | msn.comAridis (ARDS) Stock Up as Cystic Fibrosis Study Meets GoalsMarch 14, 2023 | finance.yahoo.comAridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common StockMarch 13, 2023 | msn.comAridis Skyrockets on Impressive Data In Cystic FibrosisMarch 13, 2023 | msn.comAridis stock surges ~35% as lung disease drug AR-501 meets main goal in mid-stage studyMarch 13, 2023 | finance.yahoo.comWhy Aridis Pharmaceuticals Shares Are Soaring TodayMarch 13, 2023 | marketwatch.comAridis Shares Rally Premarket on Positive Phase 2a Cystic Fibrosis Study >ARDSMarch 13, 2023 | finance.yahoo.comAridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis PatientsFebruary 17, 2023 | finanznachrichten.deInterviews with Rail Vision, Aridis Pharmaceuticals, and Digital Ally to Air on Bloomberg U.S. on the RedChip Money ReportFebruary 15, 2023 | finance.yahoo.comWhen Will Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Breakeven?February 6, 2023 | finance.yahoo.comIn virtuous cycle, foundation uses drug royalty riches to back new cystic fibrosis drug research in Bay AreaFebruary 1, 2023 | finance.yahoo.comHere's Why Aridis Pharmaceuticals (ARDS) Is a Great 'Buy the Bottom' Stock NowJanuary 27, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Aridis Pharmaceuticals (ARDS) and Acurx Pharmaceuticals (ACXP)January 26, 2023 | msn.comAridis stock slumps ~25% as antibody drug fails phase 3 trial in pneumoniaJanuary 25, 2023 | finance.yahoo.comAridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)January 25, 2023 | marketbeat.comTrading was temporarily halted for "ARDS" at 04:01 PM with a stated reason of "News pending."January 24, 2023 | marketbeat.comTrading was temporarily halted for "ARDS" at 11:01 AM with a stated reason of "LULD pause."January 17, 2023 | finance.yahoo.comNew Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial UpdateDecember 28, 2022 | finance.yahoo.comAridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25December 12, 2022 | finance.yahoo.com(Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis FoundationDecember 12, 2022 | finance.yahoo.comAridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation Get Aridis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter. Email Address He Is Giving Away Bitcoin (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin. >> Register right here ARDS Media Mentions By Week ARDS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARDS News Sentiment▼0.000.43▲Average Medical News Sentiment ARDS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARDS Articles This Week▼00▲ARDS Articles Average Week Get Aridis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: REVB News ARAV News CWBR News BPTS News NBY News MBIO News VRPX News PHIO News AGRX News SXTP News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARDS) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersNext President (Not Trump. Not Biden.)The Freeport SocietyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsProtect Your Bank Account Before It’s Too LateWeiss Ratings4 Cryptos BETTER than BitcoinTrue Market InsidersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aridis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.